MusthInsider

Latest On Voyager Therapeutics, Inc (VYGR):

Updated on: March 18, 2021

Date/Time	Type	Description	Signal
2023-05-09 19:46 EST	News	Voyager Therapeutics GAAP EPS of $2.94 beats by $1.90, revenue of $150.48M beats by $97.98M	N/A
2023-05-09 19:45 EST	News	Voyager Therapeutics, Inc. (VYGR) Q1 2023 Earnings Call Transcript	N/A
2023-05-08 16:52 EST	News	Voyager Therapeutics Q1 2023 Earnings Preview	N/A
2023-04-02 18:12 EST	News	Voyager: Preclinical Company With Major Big Pharma Deals	N/A
2023-03-08 02:10 EST	News	Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript	N/A
2023-03-07 11:26 EST	News	Voyager Therapeutics GAAP EPS of -$0.61 misses by $0.06	N/A
2023-03-06 20:49 EST	News	Voyager stock pops on getting $25M from Novartis under license deal	N/A
2023-03-06 20:49 EST	News	Voyager Therapeutics Q4 2022 Earnings Preview	N/A
2023-01-14 15:17 EST	News	Voyager: Recent Neurocrine Deal Signals More Upside	N/A
2023-01-09 21:48 EST	News	Voyager jumps 29% on licensing deal with Neurocrine	N/A
2022-11-08 21:06 EST	News	Voyager Therapeutics GAAP EPS of $0.45 beats by $0.79, revenue of $41.1M beats by $32.07M	N/A
2022-11-08 21:05 EST	News	Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript	N/A
2022-11-08 02:33 EST	News	Voyager Therapeutics Q3 2022 Earnings Preview	N/A
2022-10-04 22:59 EST	News	Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target	N/A
2022-09-07 09:01 EST	News	Voyager Therapeutics hires new finance chief	N/A
2022-08-07 13:19 EST	News	Voyager Therapeutics, Inc. (VYGR) CEO Dr. Al Sandrock on Q2 2022 Results - Earnings Call Transcript	N/A
2022-08-04 18:40 EST	News	Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02	N/A
2022-06-09 02:25 EST	News	Looking Back In On Voyager Therapeutics	N/A
2022-05-05 12:49 EST	News	Voyager Therapeutics GAAP EPS of -$0.56, revenue of $0.7M misses by $12.01M	N/A
2022-04-22 03:14 EST	News	Voyager Therapeutics plunges as board members depart	N/A
2022-03-26 15:30 EST	News	Voyager Does A Reboot After First Generation Failures	N/A
2022-03-23 17:18 EST	News	Dr. Alfred W. Sandrock is the new CEO at Voyager therapeutics	N/A
2022-03-08 21:42 EST	News	Voyager stock soars 15% on license deal with Novartis for AAV capsids for gene therapies	N/A
2022-03-08 21:42 EST	News	Voyager Therapeutics GAAP EPS of $0.15 beats by $0.47, revenue of $28.07M beats by $13.52M	N/A
2021-11-21 14:11 EST	News	Voyager Therapeutics: Another Year, Another Deal	N/A
2021-11-03 01:45 EST	News	Voyager Therapeutics EPS beats by $0.10, misses on revenue	N/A
2021-10-20 17:49 EST	News	Voyager Therapeutics falls despite gene therapy shows activity in preclinical study	N/A
2021-10-07 20:51 EST	News	Baird upgrades Voyager Therapeutics to outperform on Pfizer deal; sees ~133% upside	N/A
2021-10-06 20:28 EST	News	Pfizer in pact with Voyager Therapeutics to develop gene therapies	N/A
2021-09-22 10:09 EST	News	Voyager Therapeutics (VYGR) Investor Presentation - Slideshow	N/A
2021-08-13 23:16 EST	News	Voyager Therapeutics (VYGR) Presents At Canaccord Genuity Growth Conference Fireside Chat	N/A
2021-08-09 17:17 EST	News	Voyager launches new programs in Huntington's disease, ALS, and spinal muscular atropny	N/A
2021-07-22 08:38 EST	News	Vectoring In On Voyager Therapeutics	N/A
2021-04-26 09:15 EST	News	Voyager shares rise as FDA lifts clinical hold on Huntington’s disease treatment IND	N/A
2021-03-02 01:07 EST	Analyst Rating	The Analyst Target Price has decreased from $10.35 to $10.25.	Neutral
2021-03-01 12:35 EST	Analyst Rating	The Analyst Target Price has decreased from $11.55 to $10.35.	Neutral
2021-02-28 12:49 EST	Financials	Company financials have been released.	Neutral
2021-02-28 00:50 EST	Financials	Company financials have been released.	Neutral
2021-02-27 03:47 EST	News	Premarket analyst action - healthcare	N/A
2021-02-27 00:58 EST	Financials	Company financials have been released.	Neutral
2021-02-26 09:20 EST	News	Voyager Therapeutics EPS beats by $0.13, misses on revenue	N/A
2021-02-26 09:19 EST	News	Voyager Therapeutics, Inc. (VYGR) CEO Andre Turenne on Q4 2020 Results - Earnings Call Transcript	N/A
2021-02-26 04:54 EST	Earnings Estimate	An EPS average of -$2.86 is estimated for the 2022 year.	Sell
2021-02-26 04:54 EST	Earnings Estimate	An EPS average of -$0.55 is estimated for the quarter ending on June 30, 2021.	Sell
2021-02-04 12:59 EST	Analyst Rating	The Analyst Target Price has decreased from $14.09 to $11.55.	Neutral
2021-02-04 03:50 EST	News	Voyager sinks after BITG cut citing multiple clinical holds	N/A
2021-02-03 09:03 EST	News	Voyager gets termination notice for Neurocrine Parkinson’s collaboration	N/A
2021-01-19 04:47 EST	News	Voyager Therapeutics: Complicated Story In Gene Therapy Development	N/A
2020-12-24 17:20 EST	Analyst Rating	The Analyst Target Price has decreased from $14.75 to $14.09.	Neutral
2020-12-23 17:23 EST	Analyst Rating	The Analyst Target Price has decreased from $15.33 to $14.75.	Neutral

About Voyager Therapeutics, Inc (VYGR):

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

Name Voyager Therapeutics, Inc
Symbol VYGR
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 177
Fiscal Year EndDecember
IPO Date2015-11-11
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.voyagertherapeutics.com

Valuation

Trailing PE 5.57
Price/Sales (Trailing 12 Mt.) 1.26
Price/Book (Most Recent Quarter) 1.41
Enterprise Value Revenue 0.49
Enterprise Value EBITDA 2.7

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$2.84
Next Year EPS Estimate -$2.97
Next Quarter EPS Estimate -$0.51
Profit Margin 21%
Operating Margin 16%
Return on Assets 6%
Return on Equity 29%
Revenue 171.13 million
Earnings Per Share $0.98
Revenue Per Share $4.61
Gross Profit 62.38 million
Quarterly Earnings Growth -80%

Highlights

Market Capitalization 205.59 million
EBITDA 31.2 million
PE Ratio 3.44
Analyst Target Price $10.25
Book Value Per Share $4.13

Share Statistics

Shares Outstanding 37.65 million
Shares Float 22.58 million
% Held by Insiders 1407%
% Held by Institutions 74.93%
Shares Short 1.99 million
Shares Short Prior Month 1.89 million
Short Ratio 3.56
Short % of Float 8%
Short % of Shares Outstanding 5%

Technicals

Beta 1.06
52 Week High $14.62
52 Week Low $5.18
50 Day Moving Average 6.61
200 Day Moving Average 8.94

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

Voyager Therapeutics, Inc (VYGR) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

Voyager Therapeutics, Inc (VYGR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-02-25	$N/A	-$0.43	-$0.56	23.46%
2020-09-30	2020-11-09	$N/A	$2.27	-$0.10	2416.33%
2020-06-30	2020-08-10	$N/A	-$0.23	-$0.73	68.61%
2020-03-31	2020-05-06	$18.07 million	-$0.66	-$0.79	16.61%
2019-12-31	2020-03-03	$32.67 million	-$0.34	-$0.81	57.93%
2019-09-30	2019-11-06	$20.43 million	-$0.41	-$0.73	43.84%
2019-06-30	2019-08-09	$46.09 million	$0.29	-$0.81	135.71%
2019-03-31	2019-05-07	$5.2 million	-$0.81	-$0.78	-4.03%
2018-12-31	2019-02-26	$2.01 million	-$0.70	-$0.71	1.71%
2018-09-30	2018-11-07	$2.09 million	-$0.63	-$0.79	20.36%
2018-06-30	2018-08-07	$2.58 million	-$0.80	-$0.66	-20.61%
2018-03-31	2018-05-10	$942000	-$0.63	-$0.62	-1.61%
2017-12-31	2018-03-14	$6.35 million	-$0.40	-$0.73	44.87%
2017-09-30	2017-11-02	$1.15 million	-$0.89	-$0.72	-23.15%
2017-06-30	2017-08-08	$1.18 million	-$0.73	-$0.61	-20.66%
2017-03-31	2017-05-09	$1.46 million	-$0.65	-$0.53	-23.32%
2016-12-31	2017-03-15	$2.36 million	-$0.57	-$0.46	-24.37%
2016-09-30	2016-11-10	$3.31 million	-$0.35	-$0.41	14.22%
2016-06-30	2016-08-11	$3.72 million	-$0.37	-$0.34	-8.82%
2016-03-31	2016-05-12	$4.83 million	-$0.29	-$0.35	17.92%
2015-12-31	2016-03-17	$4.94 million	-$0.67	-$0.62	-8.06%
2015-09-30	2015-11-16	$4.94 million	-$5.25	-$3.48	-50.86%

Voyager Therapeutics, Inc (VYGR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019
Research Development	N/A	N/A	N/A	32.29 million	N/A
Income Before Tax	N/A	N/A	N/A	-24.26 million	-12.57 million
Selling General Administrative	N/A	N/A	N/A	10.21 million	9.89 million
Gross Profit	N/A	N/A	N/A	N/A	-3.88 million
Ebit	N/A	N/A	N/A	-23.59 million	-13.77 million
Operating Income	N/A	N/A	N/A	-24.43 million	-13.77 million
Income Tax Expense	N/A	N/A	N/A	N/A	N/A
Total Revenue	N/A	N/A	N/A	18.07 million	32.67 million
Cost of Revenue	N/A	N/A	N/A	N/A	36.55 million
Total Other Income Expense Net	N/A	N/A	N/A	-808000	1.19 million
Net Income From Continuing Operations	N/A	N/A	N/A	-24.26 million	-12.57 million
Net Income Applicable to Common Shares	-15.93 million	85.61 million	-8.68 million	-24.26 million	-12.57 million

Cash Flow:

Date	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019	Sep 30 2019
Investments	N/A	N/A	108.99 million	29.84 million	23.78 million
Change to Liabilities	-119.76 million	-22.15 million	N/A	-17.53 million	-6.3 million
Total Cash Flow from Investing Activities	27.36 million	-1.84 million	N/A	26.46 million	22.61 million
Net Borrowings	N/A	N/A	N/A	N/A	N/A
Total Cash Flow from Financial Activities	N/A	N/A	34000	300000	1.72 million
Change to Operating Activities	5.58 million	-1.08 million	N/A	-11.11 million	1.69 million
Change in Cash	N/A	N/A	80.23 million	3.4 million	2.76 million
Total Cash from Operating Activities	-24.74 million	-21.2 million	-28.8 million	-23.36 million	-21.58 million
Depreciation	N/A	N/A	842000	758000	715000
Other Cash Flow from Investing Activities	N/A	N/A	N/A	N/A	N/A
Change to Inventory	N/A	N/A	N/A	N/A	N/A
Change to Account Receivables	N/A	N/A	2.21 million	14.03 million	-3.97 million
Other Cash Flow from Financing Activities	N/A	N/A	N/A	N/A	N/A
Change to Net Income	2.77 million	3.97 million	N/A	3.06 million	1.29 million
Capital Expenditures	N/A	N/A	1.51 million	3.38 million	1.17 million

Balance Sheet:

Date	Dec 31 2020	Sep 30 2020	Jun 30 2020	Mar 31 2020	Dec 31 2019
Total Liabailities	N/A	N/A	N/A	242.85 million	255.25 million
Total Stockholder Equity	N/A	N/A	N/A	79.76 million	99.51 million
Other Current Liabilities	N/A	13.46 million	N/A	N/A	47.31 million
Total Assets	N/A	N/A	N/A	322.61 million	354.76 million
Common Stock	N/A	37000	37000	N/A	37000
Other Current Assets	N/A	N/A	N/A	N/A	3.95 million
Retained Earnings	N/A	-259.98 million	-345.59 million	-336.91 million	-312.65 million
Other Liabilities	N/A	33.21 million	153.04 million	N/A	148.26 million
Other Assets	N/A	1.92 million	2.18 million	N/A	1.72 million
Cash	N/A	N/A	N/A	165.23 million	86.04 million
Total Current Liabilities	N/A	42.05 million	N/A	72.54 million	76.01 million
Other Stockholder Equity	N/A	-60000	145000	N/A	-104000
Property, Plant & Equipment	N/A	49.34 million	47.19 million	N/A	46.46 million
Total Current Assets	N/A	216.31 million	N/A	272.48 million	304.66 million
Long Term Investments	N/A	N/A	N/A	1.43 million	1.92 million
Net Tangible Assets	166.24 million	166.24 million	76.88 million	99.51 million	99.51 million
Short Term Investments	N/A	N/A	N/A	85.7 million	195.49 million
Long Term Debt	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Payable	N/A	3.39 million	N/A	4.82 million	4.07 million

Voyager Therapeutics, Inc (VYGR) Chart:

Voyager Therapeutics, Inc (VYGR) News:

Below you will find a list of latest news for Voyager Therapeutics, Inc (VYGR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Voyager Therapeutics, Inc (VYGR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2024-05-17	2.5	0	CALL	0	0	886.13	TRUE	0	0
2024-05-17	5	3.51	CALL	30	40	356.72	TRUE	3.51	0
2024-05-17	7.5	1.35	CALL	8	128	113.56	TRUE	0.1	0.08
2024-05-17	10	0.25	CALL	64	472	106.4	FALSE	0	0
2024-05-17	12.5	0.06	CALL	0	50	0	FALSE	0	0
2024-05-17	15	0.27	CALL	0	26	0	FALSE	0	0
2024-05-17	17.5	0.2	CALL	0	1	0	FALSE	0	0
2024-05-17	20	0	CALL	0	0	0	FALSE	0	0
2024-05-17	2.5	0	PUT	0	0	0	FALSE	0	0
2024-05-17	5	0.05	PUT	0	20	0	FALSE	0	0
2024-05-17	7.5	0.25	PUT	30	232	102.81	FALSE	0	0
2024-05-17	10	2.41	PUT	0	81	176.62	TRUE	0	0
2024-05-17	12.5	2.55	PUT	0	10	304.35	TRUE	0	0
2024-05-17	15	0	PUT	0	0	380.91	TRUE	0	0
2024-05-17	17.5	0	PUT	0	0	436.28	TRUE	0	0
2024-05-17	20	0	PUT	0	0	474.93	TRUE	0	0
2024-06-21	2.5	0	CALL	0	0	416.73	TRUE	0	0
2024-06-21	5	2.51	CALL	0	1	67.83	TRUE	0	0
2024-06-21	7.5	0.95	CALL	0	2	75.55	TRUE	0	0
2024-06-21	10	0.45	CALL	0	39	74.25	FALSE	0	0
2024-06-21	12.5	0.07	CALL	0	1	84.71	FALSE	0	0
2024-06-21	15	0	CALL	0	0	128.2	FALSE	0	0
2024-06-21	2.5	0	PUT	0	0	0	FALSE	0	0
2024-06-21	5	0	PUT	0	0	0	FALSE	0	0
2024-06-21	7.5	0.5	PUT	0	29	76.32	FALSE	0	0
2024-06-21	10	0	PUT	0	0	64.35	TRUE	0	0
2024-06-21	12.5	0	PUT	0	0	174.61	TRUE	0	0
2024-06-21	15	0	PUT	0	0	208	TRUE	0	0
2024-07-19	2.5	0	CALL	0	0	386.73	TRUE	0	0
2024-07-19	5	3.6	CALL	37	101	57.8	TRUE	0.4	0.13
2024-07-19	7.5	1.6	CALL	0	709	64.57	TRUE	0	0
2024-07-19	10	0.45	CALL	0	262	78.7	FALSE	0	0
2024-07-19	12.5	0.25	CALL	0	75	74.8	FALSE	0	0
2024-07-19	15	0.05	CALL	0	129	0	FALSE	0	0
2024-07-19	17.5	0.5	CALL	0	7	0	FALSE	0	0
2024-07-19	20	0.2	CALL	0	31	0	FALSE	0	0
2024-07-19	2.5	0	PUT	0	0	0	FALSE	0	0
2024-07-19	5	0.27	PUT	0	173	0	FALSE	0	0
2024-07-19	7.5	0.95	PUT	0	246	65.54	FALSE	0	0
2024-07-19	10	2.5	PUT	0	94	67.14	TRUE	0	0
2024-07-19	12.5	4.2	PUT	0	7	72.2	TRUE	0	0
2024-07-19	15	6.1	PUT	0	0	88.02	TRUE	0	0
2024-07-19	17.5	0	PUT	0	0	182.75	TRUE	0	0
2024-07-19	20	0	PUT	0	0	192.84	TRUE	0	0
2024-10-18	2.5	7	CALL	0	1	267.37	TRUE	0	0
2024-10-18	5	3.2	CALL	0	3	140.4	TRUE	0	0
2024-10-18	7.5	2.2	CALL	10	244	71.5	TRUE	0.4	0.22
2024-10-18	10	1.1	CALL	0	223	63.66	FALSE	0	0
2024-10-18	12.5	0.55	CALL	0	72	71.33	FALSE	0	0
2024-10-18	15	0.3	CALL	0	40	0	FALSE	0	0
2024-10-18	17.5	0	CALL	0	0	89.6	FALSE	0	0
2024-10-18	2.5	0	PUT	0	0	0	FALSE	0	0
2024-10-18	5	0.2	PUT	0	13	0	FALSE	0	0
2024-10-18	7.5	1.47	PUT	0	45	74.2	FALSE	0	0
2024-10-18	10	3	PUT	0	19	48.57	TRUE	0	0
2024-10-18	12.5	4.2	PUT	0	3	68.95	TRUE	0	0
2024-10-18	15	6.78	PUT	0	6	89.76	TRUE	0	0
2024-10-18	17.5	9.2	PUT	0	21	125.1	TRUE	0	0

Latest VYGR Trades:

Date	Shares	Price
Jun 13, 2022 7:59 PM EST	67	$4.985
Jun 13, 2022 7:59 PM EST	3	$4.985
Jun 13, 2022 7:59 PM EST	18	$4.99
Jun 13, 2022 7:59 PM EST	17	$4.99
Jun 13, 2022 7:59 PM EST	100	$4.985

Voyager Therapeutics, Inc (VYGR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date	Form Type	Form Name	Link
2020-06-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm
2019-11-19	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1640266/000000000019015636/0000000000-19-015636-index.htm
2019-02-08	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000021545719006579/0000215457-19-006579-index.htm
2018-08-10	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000031506618002168/0000315066-18-002168-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000031506619001427/0000315066-19-001427-index.htm
2020-02-06	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000083423720006893/0000834237-20-006893-index.htm
2018-06-21	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000089924318017586/0000899243-18-017586-index.htm
2018-06-21	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000089924318017587/0000899243-18-017587-index.htm
2018-09-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000089924318024774/0000899243-18-024774-index.htm
2018-09-19	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000089924318024777/0000899243-18-024777-index.htm
2018-09-21	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000091957418006282/0000919574-18-006282-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000091957419001760/0000919574-19-001760-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000091957420001444/0000919574-20-001444-index.htm
2020-03-05	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000091957420002138/0000919574-20-002138-index.htm
2019-11-06	S-3	Registration statement under Securities Act of 1933	https://www.sec.gov/Archives/edgar/data/1640266/000104746919006100/0001047469-19-006100-index.htm
2019-12-03	424B3	Prospectus [Rule 424(b)(3)]	https://www.sec.gov/Archives/edgar/data/1640266/000104746919006602/0001047469-19-006602-index.htm
2018-03-20	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-04-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm
2018-05-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465918036438/0001104659-18-036438-index.htm
2018-06-05	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465918038314/0001104659-18-038314-index.htm
2018-06-15	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040463/0001104659-18-040463-index.htm
2018-06-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040465/0001104659-18-040465-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040887/0001104659-18-040887-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040889/0001104659-18-040889-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040890/0001104659-18-040890-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040891/0001104659-18-040891-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040892/0001104659-18-040892-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040894/0001104659-18-040894-index.htm
2018-06-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918040895/0001104659-18-040895-index.htm
2018-06-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465918042962/0001104659-18-042962-index.htm
2018-07-18	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918045812/0001104659-18-045812-index.htm
2018-07-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918045813/0001104659-18-045813-index.htm
2018-08-21	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm
2018-09-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm
2018-09-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm
2018-11-09	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465918067413/0001104659-18-067413-index.htm
2019-01-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm
2019-01-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm
2019-01-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm
2019-01-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm
2019-01-29	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919003840/0001104659-19-003840-index.htm
2019-02-22	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919009995/0001104659-19-009995-index.htm
2019-02-26	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1640266/000110465919010753/0001104659-19-010753-index.htm
2019-03-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919014279/0001104659-19-014279-index.htm
2019-04-03	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919019771/0001104659-19-019771-index.htm
2019-04-03	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm
2019-05-21	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919030857/0001104659-19-030857-index.htm
2019-05-22	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919031176/0001104659-19-031176-index.htm
2019-05-22	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm
2019-06-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035658/0001104659-19-035658-index.htm
2019-06-17	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035796/0001104659-19-035796-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035995/0001104659-19-035995-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035996/0001104659-19-035996-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035997/0001104659-19-035997-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919035998/0001104659-19-035998-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919036000/0001104659-19-036000-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919036003/0001104659-19-036003-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919036004/0001104659-19-036004-index.htm
2019-06-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465919036005/0001104659-19-036005-index.htm
2019-11-22	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1640266/000110465919066634/0001104659-19-066634-index.htm
2019-11-27	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1640266/000110465919068177/0001104659-19-068177-index.htm
2020-01-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm
2020-01-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm
2020-01-29	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm
2020-02-11	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000110465920016411/0001104659-20-016411-index.htm
2020-02-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm
2020-02-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm
2020-02-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm
2020-02-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000110465920021672/0001104659-20-021672-index.htm
2020-02-14	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920021963/0001104659-20-021963-index.htm
2020-03-03	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1640266/000110465920028678/0001104659-20-028678-index.htm
2020-03-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920035610/0001104659-20-035610-index.htm
2020-04-07	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm
2020-05-22	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070318/0001104659-20-070318-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070323/0001104659-20-070323-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070326/0001104659-20-070326-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070327/0001104659-20-070327-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070328/0001104659-20-070328-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070329/0001104659-20-070329-index.htm
2020-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920070330/0001104659-20-070330-index.htm
2020-06-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920071432/0001104659-20-071432-index.htm
2020-08-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920089624/0001104659-20-089624-index.htm
2020-09-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000110465920105222/0001104659-20-105222-index.htm
2020-09-16	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920105664/0001104659-20-105664-index.htm
2020-09-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000110465920105669/0001104659-20-105669-index.htm
2019-04-01	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000114420419017415/0001144204-19-017415-index.htm
2019-02-11	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312519033129/0001193125-19-033129-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312519037847/0001193125-19-037847-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312519037913/0001193125-19-037913-index.htm
2019-02-15	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312519042298/0001193125-19-042298-index.htm
2020-02-11	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312520030574/0001193125-20-030574-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1640266/000119312520037830/0001193125-20-037830-index.htm
2019-03-14	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000120919119019450/0001209191-19-019450-index.htm
2019-03-14	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm
2018-04-27	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1640266/000155837018003377/0001558370-18-003377-index.htm
2018-05-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837018004570/0001558370-18-004570-index.htm
2018-05-10	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837018004575/0001558370-18-004575-index.htm
2018-08-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837018006605/0001558370-18-006605-index.htm
2018-08-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837018006628/0001558370-18-006628-index.htm
2018-11-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837018008805/0001558370-18-008805-index.htm
2018-11-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837018008821/0001558370-18-008821-index.htm
2019-02-26	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837019001085/0001558370-19-001085-index.htm
2019-02-26	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1640266/000155837019001105/0001558370-19-001105-index.htm
2019-04-23	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1640266/000155837019003181/0001558370-19-003181-index.htm
2019-05-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837019004159/0001558370-19-004159-index.htm
2019-05-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837019004165/0001558370-19-004165-index.htm
2019-08-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837019007805/0001558370-19-007805-index.htm
2019-08-09	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837019007823/0001558370-19-007823-index.htm
2019-11-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837019010064/0001558370-19-010064-index.htm
2019-11-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837019010066/0001558370-19-010066-index.htm
2020-03-03	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837020001965/0001558370-20-001965-index.htm
2020-03-03	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1640266/000155837020001974/0001558370-20-001974-index.htm
2020-04-22	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1640266/000155837020004158/0001558370-20-004158-index.htm
2020-05-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837020005285/0001558370-20-005285-index.htm
2020-05-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837020005300/0001558370-20-005300-index.htm
2020-08-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1640266/000155837020010039/0001558370-20-010039-index.htm
2020-08-10	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1640266/000155837020010047/0001558370-20-010047-index.htm
2019-03-14	SC 13D	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1640266/000156459019007831/0001564590-19-007831-index.htm
2019-12-02	EFFECT	Notice of Effectiveness	https://www.sec.gov/Archives/edgar/data/1640266/999999999519002724/9999999995-19-002724-index.htm
2018-04-05	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1640266/999999999718004233/9999999997-18-004233-index.htm
2019-03-19	CT ORDER	Confidential treatment order	https://www.sec.gov/Archives/edgar/data/1640266/999999999719001305/9999999997-19-001305-index.htm

Voyager Therapeutics, Inc (VYGR) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Voyager Therapeutics, Inc (VYGR). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1407%
Institutional Ownership: 7493%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2018-04-10	Bernard Ravina	Chief Medical Officer	Sell	2,451.00	18.38	45,049.38	0.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918023708/0001104659-18-023708-index.htm
2018-03-16	Jane Henderson	CFO & SVP, Corp. Dev.	Sell	15,416.00	22.15	341,464.40	0.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-19	Jane Henderson	CFO & SVP, Corp. Dev.	Sell	1,900.00	21.76	41,344.00	0.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-22	Jane Henderson	Sr. V.P. & CFO, Corp. Dev.	Sell	19,900.00	21.07	419,293.00	0.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-23	Jane Henderson	Sr. V.P. & CFO, Corp. Dev.	Sell	11,200.00	20.52	229,824.00	0.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-23	Jane Henderson	Sr. V.P. & CFO, Corp. Dev.	Buy	11,200.00	11.97	134,064.00	11,200.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2018-03-16	Jane Henderson	CFO & SVP, Corp. Dev.	Buy	15,416.00	11.97	184,529.52	15,416.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2019-01-11	Dinah Ph.D. Sah	Chief Scientific Officer	Buy	25,000.00			163,688.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002348/0001104659-19-002348-index.htm
2020-02-10	Andre Turenne	President & CEO	Buy	81,250.00			166,795.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019448/0001104659-20-019448-index.htm
2018-03-19	Jane Henderson	CFO & SVP, Corp. Dev.	Buy	1,900.00	11.97	22,743.00	1,900.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918019018/0001104659-18-019018-index.htm
2018-03-22	Jane Henderson	Sr. V.P. & CFO, Corp. Dev.	Buy	19,900.00	11.97	238,203.00	19,900.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918020100/0001104659-18-020100-index.htm
2020-01-21	Allison Dorval	Chief Financial Officer	Sell	3,128.00	13.36	41,790.08	24,522.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008190/0001104659-20-008190-index.htm
2019-01-11	Allison Dorval	Chief Financial Officer	Buy	25,000.00			26,106.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002346/0001104659-19-002346-index.htm
2020-01-21	Matthew P. Ottmer	Chief Operating Officer	Sell	3,724.00	13.36	49,752.64	26,276.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008188/0001104659-20-008188-index.htm
2019-04-01	Robert W. Hesslein	Senior VP & General Counsel	Buy	28,125.00			28,125.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/0001104659-19-019772-index.htm
2019-01-11	Matthew P. Ottmer	Chief Operating Officer	Buy	30,000.00			30,000.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002347/0001104659-19-002347-index.htm
2019-05-20	Omar Khwaja	Officer	Buy	30,000.00			30,000.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919031178/0001104659-19-031178-index.htm
2019-03-12	NEUROCRINE BIOSCIENCES INC	10% Share Holder	Buy	4,179,728.00	11.96	49,999,996.20	4,179,728.00	https://www.sec.gov/Archives/edgar/data/1640266/000120919119019459/0001209191-19-019459-index.htm
2018-09-12	GLENN PIERCE	Director	Buy	5,000.00	18.44	92,200.00	5,000.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918056499/0001104659-18-056499-index.htm
2020-02-10	Allison Dorval	Chief Financial Officer	Buy	27,500.00			52,022.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019457/0001104659-20-019457-index.htm
2020-04-03	Robert W. Hesslein	Senior VP & General Counsel	Sell	3,091.00	8.51	26,304.41	52,534.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/0001104659-20-044247-index.htm
2020-02-10	Robert W. Hesslein	Senior VP & General Counsel	Buy	27,500.00			55,625.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/0001104659-20-019455-index.htm
2020-05-21	Omar Khwaja	Officer	Sell	3,500.00	12.96	45,360.00	56,500.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920065492/0001104659-20-065492-index.htm
2020-02-10	Omar Khwaja	Officer	Buy	30,000.00			60,000.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920019453/0001104659-20-019453-index.htm
2018-08-17	JAMES A GERAGHTY	Director	Buy	3,000.00	18.31	54,930.00	73,588.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918053030/0001104659-18-053030-index.htm
2018-09-10	JAMES A GERAGHTY	Director	Buy	3,000.00	19.39	58,170.00	76,588.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465918056500/0001104659-18-056500-index.htm
2020-01-21	Andre Turenne	President & CEO	Sell	10,705.00	13.36	143,018.80	85,545.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465920008187/0001104659-20-008187-index.htm
2019-01-11	Andre Turenne	President & CEO	Buy	96,250.00			96,250.00	https://www.sec.gov/Archives/edgar/data/1640266/000110465919002349/0001104659-19-002349-index.htm

Voyager Therapeutics, Inc

(NASDAQ:VYGR)